Efficacy of propranolol for cutaneous hemangiomas in premature children

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants. Methods: A retrospective observational study considered 24 patients who were given oral propranolol for the treatment of "problematic" IH. A multidisciplinary team, composed of a dermatologist, a pediatrician, a pediatric cardiologist, and a neonatologist, took part in the indication for propranolol and follow-up on all the patients. Propranolol was administered orally at the starting dose of 0.5-1 mg/kg/die and was gradually increased to the target dose of 2 mg/kg/die. A clinical gravity score, based on color, major diameter, thickness and texture was calculated for each IH, giving a numeric score before (t0) and after (tf) propranolol therapy. Improvement rate was evaluated in terms of score percentage difference between t0 and tf. Results: All of the IH except one (96%), showed a variable grade of improvement, with a median score improvement of 69.1%. Median initial score in premature and term infants did not show any significant difference (P=0.38). Otherwise the two subgroups showed a significant difference in final scores: medium percentage improvement in premature and term infants, was respectively 80.9% and 49.6% (P<0.01). No significant side effects were reported during the treatment period. Conclusions: As pointed out in our study, IH in premature children showed a significantly better response to propranolol treatment.

Original languageEnglish
Pages (from-to)485-491
Number of pages7
JournalGiornale Italiano di Dermatologia e Venereologia
Volume151
Issue number5
Publication statusPublished - 2016

Fingerprint

Hemangioma
Propranolol
Skin
Premature Infants
Gravitation
Therapeutics
Observational Studies
Retrospective Studies
Color
Pediatrics
Safety

Keywords

  • Hemangiomas
  • Premature infant
  • Propranolol

ASJC Scopus subject areas

  • Medicine(all)
  • Dermatology

Cite this

@article{9d1110f5ebd746ebb942dd1cf8482922,
title = "Efficacy of propranolol for cutaneous hemangiomas in premature children",
abstract = "Background: The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants. Methods: A retrospective observational study considered 24 patients who were given oral propranolol for the treatment of {"}problematic{"} IH. A multidisciplinary team, composed of a dermatologist, a pediatrician, a pediatric cardiologist, and a neonatologist, took part in the indication for propranolol and follow-up on all the patients. Propranolol was administered orally at the starting dose of 0.5-1 mg/kg/die and was gradually increased to the target dose of 2 mg/kg/die. A clinical gravity score, based on color, major diameter, thickness and texture was calculated for each IH, giving a numeric score before (t0) and after (tf) propranolol therapy. Improvement rate was evaluated in terms of score percentage difference between t0 and tf. Results: All of the IH except one (96{\%}), showed a variable grade of improvement, with a median score improvement of 69.1{\%}. Median initial score in premature and term infants did not show any significant difference (P=0.38). Otherwise the two subgroups showed a significant difference in final scores: medium percentage improvement in premature and term infants, was respectively 80.9{\%} and 49.6{\%} (P<0.01). No significant side effects were reported during the treatment period. Conclusions: As pointed out in our study, IH in premature children showed a significantly better response to propranolol treatment.",
keywords = "Hemangiomas, Premature infant, Propranolol",
author = "Valeria Brazzeli and Chiara Giorgini and Stefania Barruscotti and Codazzi, {Claudia A.} and Savina Mannarino and Chryssoula Tzialla and Mauro Stronati and Marseglia, {Gian Luigi} and Giovanni Boroni",
year = "2016",
language = "English",
volume = "151",
pages = "485--491",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - Efficacy of propranolol for cutaneous hemangiomas in premature children

AU - Brazzeli, Valeria

AU - Giorgini, Chiara

AU - Barruscotti, Stefania

AU - Codazzi, Claudia A.

AU - Mannarino, Savina

AU - Tzialla, Chryssoula

AU - Stronati, Mauro

AU - Marseglia, Gian Luigi

AU - Boroni, Giovanni

PY - 2016

Y1 - 2016

N2 - Background: The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants. Methods: A retrospective observational study considered 24 patients who were given oral propranolol for the treatment of "problematic" IH. A multidisciplinary team, composed of a dermatologist, a pediatrician, a pediatric cardiologist, and a neonatologist, took part in the indication for propranolol and follow-up on all the patients. Propranolol was administered orally at the starting dose of 0.5-1 mg/kg/die and was gradually increased to the target dose of 2 mg/kg/die. A clinical gravity score, based on color, major diameter, thickness and texture was calculated for each IH, giving a numeric score before (t0) and after (tf) propranolol therapy. Improvement rate was evaluated in terms of score percentage difference between t0 and tf. Results: All of the IH except one (96%), showed a variable grade of improvement, with a median score improvement of 69.1%. Median initial score in premature and term infants did not show any significant difference (P=0.38). Otherwise the two subgroups showed a significant difference in final scores: medium percentage improvement in premature and term infants, was respectively 80.9% and 49.6% (P<0.01). No significant side effects were reported during the treatment period. Conclusions: As pointed out in our study, IH in premature children showed a significantly better response to propranolol treatment.

AB - Background: The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants. Methods: A retrospective observational study considered 24 patients who were given oral propranolol for the treatment of "problematic" IH. A multidisciplinary team, composed of a dermatologist, a pediatrician, a pediatric cardiologist, and a neonatologist, took part in the indication for propranolol and follow-up on all the patients. Propranolol was administered orally at the starting dose of 0.5-1 mg/kg/die and was gradually increased to the target dose of 2 mg/kg/die. A clinical gravity score, based on color, major diameter, thickness and texture was calculated for each IH, giving a numeric score before (t0) and after (tf) propranolol therapy. Improvement rate was evaluated in terms of score percentage difference between t0 and tf. Results: All of the IH except one (96%), showed a variable grade of improvement, with a median score improvement of 69.1%. Median initial score in premature and term infants did not show any significant difference (P=0.38). Otherwise the two subgroups showed a significant difference in final scores: medium percentage improvement in premature and term infants, was respectively 80.9% and 49.6% (P<0.01). No significant side effects were reported during the treatment period. Conclusions: As pointed out in our study, IH in premature children showed a significantly better response to propranolol treatment.

KW - Hemangiomas

KW - Premature infant

KW - Propranolol

UR - http://www.scopus.com/inward/record.url?scp=84991234554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991234554&partnerID=8YFLogxK

M3 - Article

VL - 151

SP - 485

EP - 491

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 5

ER -